Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospec...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1998-06, Vol.351 (9117), p.1682-1686
Main Authors: Li, TS, Tubiana, R, Katlama, C, Calvez, V, Mohand, H Ait, Autran, B
Format: Article
Language:English
Subjects:
Adult
AIDS/HIV
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antibodies, Monoclonal
Antiretroviral agents
Antiviral agents
Biological and medical sciences
CD4-Positive T-Lymphocytes - physiology
Cell Division
Cells
Drug therapy
Female
HIV
HIV Infections - drug therapy
HIV Infections - immunology
HIV-1 - genetics
Human immunodeficiency virus
Humans
Immunocompetence
Indinavir - therapeutic use
Male
Medical sciences
Microorganisms
Middle Aged
Pharmacology. Drug treatments
Pilot Projects
Prospective Studies
Protease Inhibitors - therapeutic use
Proteinase inhibitors
Reverse Transcriptase Inhibitors - therapeutic use
Ritonavir - therapeutic use
RNA, Viral - analysis
Time Factors
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c468t-84426333cb08ba10e14d56644e237ebdbd8c9d0f27d710df2b470b7c1223dc863
cites cdi_FETCH-LOGICAL-c468t-84426333cb08ba10e14d56644e237ebdbd8c9d0f27d710df2b470b7c1223dc863
container_end_page 1686
container_issue 9117
container_start_page 1682
container_title The Lancet (British edition)
container_volume 351
creator Li, TS
Tubiana, R
Katlama, C
Calvez, V
Mohand, H Ait
Autran, B
description Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospective pilot study to address these issues. Both treatment-naïve and previously treated patients were included. 20 patients (seven naïve, 13 previously treated) were treated with one protease inhibitor and two reverse-transcriptase inhibitors and followed up for 12 months. We measured CD4-cell proliferation in response to cytomegalovirus and tuberculin antigens and counted subsets of CD4 cells at baseline and months 1, 3, 6, 9, and 12. Patients who had no antigen-specific reactivity at baseline but developed it while receiving HAART were classified as immunological responders. Four patients had antigen-specific reactivity at baseline compared with 14 at month 12 (p
doi_str_mv 10.1016/S0140-6736(97)10291-4
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73884028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673697102914</els_id><sourcerecordid>73884028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-84426333cb08ba10e14d56644e237ebdbd8c9d0f27d710df2b470b7c1223dc863</originalsourceid><addsrcrecordid>eNqFkc2O0zAUhS0EGsrAI4xkIYRgYfBf4mSFUPmZkSqxYEDsLMe-aT1K42InkfoKPDVOG3XBhpUl3-8c3XsOQjeMvmOUle-_UyYpKZUo39TqLaO8ZkQ-QismlSSFVL8eo9UFeYqepfRAKZUlLa7QVa2ErCq5Qn82od-SzqTB91scwYYJ4hH7Hq8_SXxPLHQdbsfeDj702PQOTz6ajnTBuIy7cRm0A0S889tdd8Qm_02Q4cFHGGI4KfCwg2gOJ2vjJtNbcPj27idh2PkEJsFz9KQ1XYIXy3uNfnz5fL--JZtvX-_WHzfEyrIaSCUlL4UQtqFVYxgFJl1RllICFwoa17jK1o62XDnFqGt5IxVtlGWcC2erUlyj12ffQwy_R0iD3vs032l6CGPSSuRkKK8y-PIf8CGMsc-7aVbXVLCiohkqzpCNIaUIrT5EvzfxqBnVc1H6VJSeW9C10qeitMy6m8V8bPbgLqqlmTx_tcxNsqZrY07MpwvGuaxVMWMfzhjkxCYPUSfrYQ43Z28H7YL_zyJ_AV5Qr7U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199031580</pqid></control><display><type>article</type><title>Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease</title><source>ScienceDirect Freedom Collection</source><source>BSC - Ebsco (Business Source Ultimate)</source><creator>Li, TS ; Tubiana, R ; Katlama, C ; Calvez, V ; Mohand, H Ait ; Autran, B</creator><creatorcontrib>Li, TS ; Tubiana, R ; Katlama, C ; Calvez, V ; Mohand, H Ait ; Autran, B</creatorcontrib><description>Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospective pilot study to address these issues. Both treatment-naïve and previously treated patients were included. 20 patients (seven naïve, 13 previously treated) were treated with one protease inhibitor and two reverse-transcriptase inhibitors and followed up for 12 months. We measured CD4-cell proliferation in response to cytomegalovirus and tuberculin antigens and counted subsets of CD4 cells at baseline and months 1, 3, 6, 9, and 12. Patients who had no antigen-specific reactivity at baseline but developed it while receiving HAART were classified as immunological responders. Four patients had antigen-specific reactivity at baseline compared with 14 at month 12 (p&lt;0·001). Between month 3 and month 12 viral load fell by a median of 1·5 log copies/mL from baseline (4·6 log copies/mL) and CD4-cell count increased by a median of 63/μ/L (from 93/μ/L). Ten patients (six of seven naïve, four of 13 previously treated) were immunological responders. They differed significantly from the ten non-responders in that their viral-load reduction was sustained for 12 months, the increase in CD4 count was greater, and they showed an early increase in memory CD4 T cells with an increase of naïve T cells. HAART can induce sustained recovery of CD4 T-cell reactivity against opportunistic pathogens in severely immunosuppressed patients. This recovery depends not on baseline values but on the amplitude and duration of viral-load reduction and the increase of memory CD4 T cells.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(97)10291-4</identifier><identifier>PMID: 9734884</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Adult ; AIDS/HIV ; Anti-HIV Agents - therapeutic use ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antibodies, Monoclonal ; Antiretroviral agents ; Antiviral agents ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - physiology ; Cell Division ; Cells ; Drug therapy ; Female ; HIV ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV-1 - genetics ; Human immunodeficiency virus ; Humans ; Immunocompetence ; Indinavir - therapeutic use ; Male ; Medical sciences ; Microorganisms ; Middle Aged ; Pharmacology. Drug treatments ; Pilot Projects ; Prospective Studies ; Protease Inhibitors - therapeutic use ; Proteinase inhibitors ; Reverse Transcriptase Inhibitors - therapeutic use ; Ritonavir - therapeutic use ; RNA, Viral - analysis ; Time Factors ; Viral Load</subject><ispartof>The Lancet (British edition), 1998-06, Vol.351 (9117), p.1682-1686</ispartof><rights>1998 Elsevier Ltd</rights><rights>1998 INIST-CNRS</rights><rights>Copyright Lancet Ltd. Jun 6, 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-84426333cb08ba10e14d56644e237ebdbd8c9d0f27d710df2b470b7c1223dc863</citedby><cites>FETCH-LOGICAL-c468t-84426333cb08ba10e14d56644e237ebdbd8c9d0f27d710df2b470b7c1223dc863</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2249754$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9734884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, TS</creatorcontrib><creatorcontrib>Tubiana, R</creatorcontrib><creatorcontrib>Katlama, C</creatorcontrib><creatorcontrib>Calvez, V</creatorcontrib><creatorcontrib>Mohand, H Ait</creatorcontrib><creatorcontrib>Autran, B</creatorcontrib><title>Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospective pilot study to address these issues. Both treatment-naïve and previously treated patients were included. 20 patients (seven naïve, 13 previously treated) were treated with one protease inhibitor and two reverse-transcriptase inhibitors and followed up for 12 months. We measured CD4-cell proliferation in response to cytomegalovirus and tuberculin antigens and counted subsets of CD4 cells at baseline and months 1, 3, 6, 9, and 12. Patients who had no antigen-specific reactivity at baseline but developed it while receiving HAART were classified as immunological responders. Four patients had antigen-specific reactivity at baseline compared with 14 at month 12 (p&lt;0·001). Between month 3 and month 12 viral load fell by a median of 1·5 log copies/mL from baseline (4·6 log copies/mL) and CD4-cell count increased by a median of 63/μ/L (from 93/μ/L). Ten patients (six of seven naïve, four of 13 previously treated) were immunological responders. They differed significantly from the ten non-responders in that their viral-load reduction was sustained for 12 months, the increase in CD4 count was greater, and they showed an early increase in memory CD4 T cells with an increase of naïve T cells. HAART can induce sustained recovery of CD4 T-cell reactivity against opportunistic pathogens in severely immunosuppressed patients. This recovery depends not on baseline values but on the amplitude and duration of viral-load reduction and the increase of memory CD4 T cells.</description><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antibodies, Monoclonal</subject><subject>Antiretroviral agents</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - physiology</subject><subject>Cell Division</subject><subject>Cells</subject><subject>Drug therapy</subject><subject>Female</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV-1 - genetics</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunocompetence</subject><subject>Indinavir - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microorganisms</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Prospective Studies</subject><subject>Protease Inhibitors - therapeutic use</subject><subject>Proteinase inhibitors</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Ritonavir - therapeutic use</subject><subject>RNA, Viral - analysis</subject><subject>Time Factors</subject><subject>Viral Load</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNqFkc2O0zAUhS0EGsrAI4xkIYRgYfBf4mSFUPmZkSqxYEDsLMe-aT1K42InkfoKPDVOG3XBhpUl3-8c3XsOQjeMvmOUle-_UyYpKZUo39TqLaO8ZkQ-QismlSSFVL8eo9UFeYqepfRAKZUlLa7QVa2ErCq5Qn82od-SzqTB91scwYYJ4hH7Hq8_SXxPLHQdbsfeDj702PQOTz6ajnTBuIy7cRm0A0S889tdd8Qm_02Q4cFHGGI4KfCwg2gOJ2vjJtNbcPj27idh2PkEJsFz9KQ1XYIXy3uNfnz5fL--JZtvX-_WHzfEyrIaSCUlL4UQtqFVYxgFJl1RllICFwoa17jK1o62XDnFqGt5IxVtlGWcC2erUlyj12ffQwy_R0iD3vs032l6CGPSSuRkKK8y-PIf8CGMsc-7aVbXVLCiohkqzpCNIaUIrT5EvzfxqBnVc1H6VJSeW9C10qeitMy6m8V8bPbgLqqlmTx_tcxNsqZrY07MpwvGuaxVMWMfzhjkxCYPUSfrYQ43Z28H7YL_zyJ_AV5Qr7U</recordid><startdate>19980606</startdate><enddate>19980606</enddate><creator>Li, TS</creator><creator>Tubiana, R</creator><creator>Katlama, C</creator><creator>Calvez, V</creator><creator>Mohand, H Ait</creator><creator>Autran, B</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>19980606</creationdate><title>Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease</title><author>Li, TS ; Tubiana, R ; Katlama, C ; Calvez, V ; Mohand, H Ait ; Autran, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-84426333cb08ba10e14d56644e237ebdbd8c9d0f27d710df2b470b7c1223dc863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antibodies, Monoclonal</topic><topic>Antiretroviral agents</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - physiology</topic><topic>Cell Division</topic><topic>Cells</topic><topic>Drug therapy</topic><topic>Female</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV-1 - genetics</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunocompetence</topic><topic>Indinavir - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microorganisms</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Prospective Studies</topic><topic>Protease Inhibitors - therapeutic use</topic><topic>Proteinase inhibitors</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Ritonavir - therapeutic use</topic><topic>RNA, Viral - analysis</topic><topic>Time Factors</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, TS</creatorcontrib><creatorcontrib>Tubiana, R</creatorcontrib><creatorcontrib>Katlama, C</creatorcontrib><creatorcontrib>Calvez, V</creatorcontrib><creatorcontrib>Mohand, H Ait</creatorcontrib><creatorcontrib>Autran, B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medicine (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, TS</au><au>Tubiana, R</au><au>Katlama, C</au><au>Calvez, V</au><au>Mohand, H Ait</au><au>Autran, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1998-06-06</date><risdate>1998</risdate><volume>351</volume><issue>9117</issue><spage>1682</spage><epage>1686</epage><pages>1682-1686</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospective pilot study to address these issues. Both treatment-naïve and previously treated patients were included. 20 patients (seven naïve, 13 previously treated) were treated with one protease inhibitor and two reverse-transcriptase inhibitors and followed up for 12 months. We measured CD4-cell proliferation in response to cytomegalovirus and tuberculin antigens and counted subsets of CD4 cells at baseline and months 1, 3, 6, 9, and 12. Patients who had no antigen-specific reactivity at baseline but developed it while receiving HAART were classified as immunological responders. Four patients had antigen-specific reactivity at baseline compared with 14 at month 12 (p&lt;0·001). Between month 3 and month 12 viral load fell by a median of 1·5 log copies/mL from baseline (4·6 log copies/mL) and CD4-cell count increased by a median of 63/μ/L (from 93/μ/L). Ten patients (six of seven naïve, four of 13 previously treated) were immunological responders. They differed significantly from the ten non-responders in that their viral-load reduction was sustained for 12 months, the increase in CD4 count was greater, and they showed an early increase in memory CD4 T cells with an increase of naïve T cells. HAART can induce sustained recovery of CD4 T-cell reactivity against opportunistic pathogens in severely immunosuppressed patients. This recovery depends not on baseline values but on the amplitude and duration of viral-load reduction and the increase of memory CD4 T cells.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>9734884</pmid><doi>10.1016/S0140-6736(97)10291-4</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 1998-06, Vol.351 (9117), p.1682-1686
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_miscellaneous_73884028
source ScienceDirect Freedom Collection; BSC - Ebsco (Business Source Ultimate)
subjects Adult
AIDS/HIV
Anti-HIV Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antibodies, Monoclonal
Antiretroviral agents
Antiviral agents
Biological and medical sciences
CD4-Positive T-Lymphocytes - physiology
Cell Division
Cells
Drug therapy
Female
HIV
HIV Infections - drug therapy
HIV Infections - immunology
HIV-1 - genetics
Human immunodeficiency virus
Humans
Immunocompetence
Indinavir - therapeutic use
Male
Medical sciences
Microorganisms
Middle Aged
Pharmacology. Drug treatments
Pilot Projects
Prospective Studies
Protease Inhibitors - therapeutic use
Proteinase inhibitors
Reverse Transcriptase Inhibitors - therapeutic use
Ritonavir - therapeutic use
RNA, Viral - analysis
Time Factors
Viral Load
title Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A27%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-lasting%20recovery%20in%20CD4%20T-cell%20function%20and%20viral-load%20reduction%20after%20highly%20active%20antiretroviral%20therapy%20in%20advanced%20HIV-1%20disease&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Li,%20TS&rft.date=1998-06-06&rft.volume=351&rft.issue=9117&rft.spage=1682&rft.epage=1686&rft.pages=1682-1686&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(97)10291-4&rft_dat=%3Cproquest_cross%3E73884028%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c468t-84426333cb08ba10e14d56644e237ebdbd8c9d0f27d710df2b470b7c1223dc863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=199031580&rft_id=info:pmid/9734884&rfr_iscdi=true